• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Omeros unlocks 20% of Class A orphans

Omeros unlocks 20% of Class A orphans

November 30, 2011
CenterWatch Staff

Omeros has reported that with its identification of compounds that interact
selectively with each of four additional orphan G protein-coupled receptors (GPCRs) - GPR19, GPR20, GPR31 and GPR141 - it has now unlocked over 20% of the 77 Class A orphans. GPCRs represent the premier family of drug targets, with more than 30% of currently marketed drugs targeting only 46 GPCRs. There are approximately 120 orphan GPCRs, and Omeros is initially targeting Class A orphan GPCRs.

The four additional orphan receptors unlocked by Omeros are linked to important potential indications. GPR19 has been tied to metastatic melanoma, the most advanced stage of melanoma. GPR20 and GPR141 are expressed in areas of the body associated with gastrointestinal disorders and respiratory/immunologic disorders, respectively. GPR31 has been implicated in anxiety disorders, which affect approximately 40 million adults in the United States in a given year. By identifying compounds that interact selectively with each of these four orphan receptors - as for the other 14 orphan GPCRs that it has previously unlocked - Omeros is able to provide templates to the pharmaceutical industry for the design of proprietary compounds that interact with these receptors.

"We continue to march through the Class A orphan GPCRs and have initiated
compound optimization," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "In parallel, we are executing on our intellectual property strategy to protect each unlocked target through a multipronged approach directed to compound structures, uniquely identified signaling pathways and associated therapeutic indications. Collectively, this approach provides us the opportunity to establish broad and enforceable protection for each receptor that we unlock."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing